ArticleFrontiers in cardiovascular medicine2026
The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Evidence for the first-line treatment of venous thromboembolism (VTE) by use of direct oral anticoagulants (DOACs) is based on stratification by body-mass index (BMI) and total body weight, but does not consider body composition - defined as the distribution of fat mass (FM) and fat-free mass (FFM). Variability in body composition exists among patients with normal BMI, but is anticipated to be markedly greater in the context of overweight and obesity. Methods: The BIARIVA prospective, single-center, cross-sectional study was conducted to assess whether body composition affects blood coagulation monitoring parameters in patients on therapeutic-dose anticoagulant treatment for VTE with oral factor (F.) Xa inhibitors rivaroxaban or edoxaban. Patients were qualified for inclusion into the study if they were categorized into one of the specified BMI categories; 18-25, 30-35, or > 35 kg/m Results: Thirty-six patients on rivaroxaban and 35 patients on edoxaban were finally analyzed. The main finding in this study was a significant negative correlation observed in the edoxaban group for the absolute FFM with anti-F.Xa and plasma concentration peak levels (BIA method 1: r Conclusions: This study suggests that body composition might influence specific coagulation measurements in patients treated with edoxaban, but further research is required to finally determine the role of body composition in this context and to evaluate clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.